Advanced Search

Study Preview



Study Title and Description

Safety aspects and cholesterol-lowering efficacy of chitosan tablets.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Safety aspects and cholesterol-lowering efficacy of chitosan tablets.
Author Tapola NS., Lyyra ML., Kolehmainen RM., Sarkkinen ES., Schauss AG.
Country Oy Foodfiles Ltd, Neulaniementie, Finland.
Year 2008
Numbers Pubmed ID: 18460478

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2008
  • Comments Comments (
    0
    ) |
country Finland
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
blindness Single blind
  • Comments Comments (
    0
    ) |
diet Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
feedcontrol Food partially provided
  • Comments Comments (
    0
    ) |
sampsize 65
  • Comments Comments (
    0
    ) |
runin Yes
  • Comments Comments (
    0
    ) |
washout Not applicable
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean ~46.25
  • Comments Comments (
    0
    ) |
age_range
  • Comments Comments (
    0
    ) |
bmi_mean ~26
  • Comments Comments (
    0
    ) |
bmi_range
  • Comments Comments (
    0
    ) |
blhealth_healthy
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth 1
  • Comments Comments (
    0
    ) |
blhealth_othspec plasma total cholesterol 5.0-6.5 mmol/L
  • Comments Comments (
    0
    ) |
gender ~48.2
  • Comments Comments (
    0
    ) |
ftype1 Chitosan
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 4.5
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1 ~55 days
  • Comments Comments (
    0
    ) |
admin1 Tablet
  • Comments Comments (
    0
    ) |
ftype2 Chitosan
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1 6.75
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2 ~55
  • Comments Comments (
    0
    ) |
admin2 Tablet
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 Active Placebo, glucomannan (no chitosan)
  • Comments Comments (
    0
    ) |
cdose1 0
  • Comments Comments (
    0
    ) |
cduration1 ~54
  • Comments Comments (
    0
    ) |
cadmin1 Tablet
  • Comments Comments (
    0
    ) |
comparator2 Placebo
  • Comments Comments (
    0
    ) |
cdose2 0
  • Comments Comments (
    0
    ) |
cduration2 ~55
  • Comments Comments (
    0
    ) |
cadmin2 Tablet
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.